Melanoma vaccines: developments over the past 10 years

References

• Parmiani G, Castelli C, Santinami M, Rivoltini L. Melanoma immunology: past, present and future. Curr. Opin. Oncol.19(2), 121–127 (2007).
   PubMed Web of Science ®Google Scholar
• Cebon J, Gedye C, John T, Davis ID. Immunotherapy of advanced or metastatic melanoma. Clin. Adv. Hematol. Oncol.5(12), 994–1006 (2007).
   PubMedGoogle Scholar
• Morton DL, Eilber FR, Joseph WL, Wood WC, Trahan E, Ketcham AS. Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy. Ann. Surg.172(4), 740–749 (1970).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med.10(9), 909–915 (2004).
   PubMed Web of Science ®Google Scholar
• Jandus C, Speiser D, Romero P. Recent advances and hurdles in melanoma immunotherapy. Pigment Cell Melanoma Res.22(6), 711–723 (2009).
   PubMedGoogle Scholar
• Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB–III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol.19(9), 2370–2380 (2001).
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.363(8), 711–723 (2010).
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med.363(9), 809–819 (2010).
   PubMed Web of Science ®Google Scholar
• Kono M, Dunn IS, Durda PJ et al. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol. Cancer Res.4(10), 779–792 (2006).
   PubMed Web of Science ®Google Scholar
• Boni A, Cogdill AP, Dang P et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res.70(13), 5213–5219 (2010).
   PubMed Web of Science ®Google Scholar
• Barrow C, Browning J, Macgregor D et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin. Cancer Res.12(3), 764–771 (2006).
   PubMed Web of Science ®Google Scholar
• Nicholaou T, Ebert LM, Davis ID et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin. Cancer Res.15, 2166–2173 (2009).
   PubMed Web of Science ®Google Scholar
• Chen Q, Daniel V, Maher DW, Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int. J. Cancer56, 755–760 (1994).
   PubMed Web of Science ®Google Scholar
• Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat. Rev. Cancer8(11), 887–899 (2008).
   PubMed Web of Science ®Google Scholar
• Attig S, Hennenlotter J, Pawelec G et al. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res.69(21), 8412–8419 (2009).
   PubMed Web of Science ®Google Scholar
• Leonard JP, Sherman ML, Fisher GL et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood90(7), 2541–2548 (1997).
   PubMed Web of Science ®Google Scholar
• Suntharalingam G, Perry MR, Ward S et al. Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med.355(10), 1018–1028 (2006).
   PubMed Web of Science ®Google Scholar
• Davis ID, Chen W, Jackson H et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proc. Natl Acad. Sci. USA101(29), 10697–10702 (2004).
   PubMed Web of Science ®Google Scholar
• Noguchi Y, Richards EC, Chen YT, Old LJ. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl Acad. Sci. USA92(6), 2219–2223 (1995).
   PubMed Web of Science ®Google Scholar
• Gan HK, Grothey A, Pond GR, Moore MJ, Siu LL, Sargent D. Randomized Phase II trials: inevitable or inadvisable? J. Clin. Oncol.28(15), 2641–2647 (2010).
   PubMed Web of Science ®Google Scholar
• Brufsky A. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. Am. J. Clin. Oncol.33(2), 186–195 (2010).
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med.359(17), 1757–1765 (2008).
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res.15(23), 7412–7420 (2009).
   PubMed Web of Science ®Google Scholar
• Hoos A, Eggermont AM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst.102(18), 1388–1397 (2010).
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Petroni GR, Chianese-Bullock KA et al. Immunologic and clinical outcomes of a randomized Phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin. Cancer Res.13(21), 6386–6395 (2007).
   PubMed Web of Science ®Google Scholar
• Van Baren N, Bonnet MC, Dreno B et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol.23(35), 9008–9021 (2005).
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Yamshchikov GV, Hogan KT et al. Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines. Ann. Surg. Oncol.15(12), 3538–3549 (2008).
   PubMedGoogle Scholar
• Carrasco J, Van Pel A, Neyns B et al. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J. Immunol.180(5), 3585–3593 (2008).
   PubMed Web of Science ®Google Scholar
• Cebon J, Knights A, Ebert L, Jackson H, Chen W. Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1. Expert Rev. Vaccines9(6), 617–629 (2010).
   PubMed Web of Science ®Google Scholar
• Jung T, Schauer U, Heusser C, Neumann C, Rieger C. Detection of intracellular cytokines by flow cytometry. J. Immunol. Methods159(1–2), 197–207 (1993).
   PubMed Web of Science ®Google Scholar
• Jackson HM, Dimopoulos N, Chen Q et al. A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples. J. Immunol. Methods291(1–2), 51–62 (2004).
   PubMedGoogle Scholar
• Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods65(1–2), 109–121 (1983).
   PubMed Web of Science ®Google Scholar
• Fujihashi K, Mcghee JR, Beagley KW et al. Cytokine-specific ELISPOT assay. Single cell analysis of IL-2, IL-4 and IL-6 producing cells. J. Immunol. Methods160(2), 181–189 (1993).
   PubMed Web of Science ®Google Scholar
• Schmittel A, Keilholz U, Scheibenbogen C. Evaluation of the interferon-γ ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J. Immunol. Methods210(2), 167–174 (1997).
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Jager E, Chen W et al. CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc. Natl Acad. Sci. USA99(18), 11813–11818 (2002).
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Nagata Y, Jager E et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc. Natl Acad. Sci. USA97(20), 10917–10922 (2000).
   PubMed Web of Science ®Google Scholar
• Jackson H, Dimopoulos N, Mifsud NA et al. Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1. J. Immunol.176(10), 5908–5917 (2006).
   PubMedGoogle Scholar
• Baumgaertner P, Rufer N, Devevre E et al. Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens. Cancer Res.66(4), 1912–1916 (2006).
   PubMedGoogle Scholar
• Bercovici N, Haicheur N, Massicard S et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J. Immunother.31(1), 101–112 (2008).
   PubMedGoogle Scholar
• Chen W, Mccluskey J. Immunodominance and immunodomination: critical factors in developing effective CD8(+) T-cell-based cancer vaccines. Adv. Cancer Res.95, 203–247 (2006).
   PubMed Web of Science ®Google Scholar
• Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Ann. Rev. Immunol.17, 51–88 (1999).
   PubMed Web of Science ®Google Scholar
• Altman JD, Moss PA, Goulder PJ et al. Phenotypic analysis of antigen-specific T lymphocytes. Science274(5284), 94–96. (1996).
   PubMed Web of Science ®Google Scholar
• Pittet MJ, Zippelius A, Speiser DE et al. Ex vivo IFN-γ secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J. Immunol.166(12), 7634–7640 (2001).
   PubMed Web of Science ®Google Scholar
• Jandus C, Bioley G, Dojcinovic D et al. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res.69(20), 8085–8093 (2009).
   PubMedGoogle Scholar
• Speiser DE, Baumgaertner P, Barbey C et al. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J. Immunol.177(2), 1338–1348 (2006).
   PubMed Web of Science ®Google Scholar
• Walker EB, Haley D, Miller W et al. gp100(209–2M) peptide immunization of human lymphocyte antigen-A2+ stage I–III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin. Cancer Res.10(2), 668–680 (2004).
   PubMed Web of Science ®Google Scholar
• Dimopoulos N, Jackson HM, Ebert L et al. Combining MHC tetramer and intracellular cytokine staining for CD8(+) T cells to reveal antigenic epitopes naturally presented on tumor cells. J. Immunol. Methods340(1), 90–94 (2009).
   PubMedGoogle Scholar
• Yewdell JW. Designing CD8+ T cell vaccines: it’s not rocket science (yet). Curr. Opin. Immunol.22(3), 402–410 (2010).
   PubMedGoogle Scholar
• Bijker MS, Van Den Eeden SJ, Franken KL, Melief CJ, Van Der Burg SH, Offringa R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur. J. Immunol.38(4), 1033–1042 (2008).
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med.361(19), 1838–1847 (2009).
   PubMed Web of Science ®Google Scholar
• Melief CJ, Van Der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev.8(5), 351–360 (2008).
   Google Scholar
• Engelhard VH, Altrich-Vanlith M, Ostankovitch M, Zarling AL. Post-translational modifications of naturally processed MHC-binding epitopes. Curr. Opin. Immunol.18(1), 92–97 (2006).
   PubMed Web of Science ®Google Scholar
• Petersen J, Purcell AW, Rossjohn J. Post-translationally modified T cell epitopes: immune recognition and immunotherapy. J. Molec. Med. (Berlin, Germany)87(11), 1045–1051 (2009).
   PubMed Web of Science ®Google Scholar
• Schnurr M, Chen Q, Shin A et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood105(6), 2465–2472 (2005).
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Atanackovic D, Matsuo M et al. Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs. J. Immunol.170(3), 1191–1196 (2003).
   PubMedGoogle Scholar
• Valmori D, Souleimanian NE, Tosello V et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc. Natl Acad. Sci. USA104(21), 8947–8952 (2007).
   PubMed Web of Science ®Google Scholar
• Poulin LF, Salio M, Griessinger E et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8α+ dendritic cells. J. Exp. Med.207(6), 1261–1271 (2010).
   PubMed Web of Science ®Google Scholar
• Caminschi I, Proietto AI, Ahmet F et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood112(8), 3264–3273 (2008).
   PubMed Web of Science ®Google Scholar
• Joffre OP, Sancho D, Zelenay S, Keller AM, Reis E, Sousa C. Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A. Eur. J. Immunol.40(5), 1255–1265 (2010).
   PubMedGoogle Scholar
• Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat. Rev. Genet.9(10), 776–788 (2008).
   PubMed Web of Science ®Google Scholar
• Dannull J, Lesher DT, Holzknecht R et al. Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. Blood110(13), 4341–4350 (2007).
   PubMed Web of Science ®Google Scholar
• Kastenmuller W, Gasteiger G, Gronau JH et al. Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination. J. Exp. Med.204(9), 2187–2198 (2007).
   PubMedGoogle Scholar
• Hansen TH, Bouvier M. MHC class I antigen presentation: learning from viral evasion strategies. Nat. Rev. Immunol.9(7), 503–513 (2009).
   PubMedGoogle Scholar
• Pascolo S. Messenger RNA-based vaccines. Expert Opin. Biol. Therapy4(8), 1285–1294 (2004).
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Rosenberg SA. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int. Rev. Immunol.14(2–3), 173–192 (1997).
   PubMedGoogle Scholar
• Kawakami Y, Robbins PF, Wang RF, Parkhurst M, Kang X, Rosenberg SA. The use of melanosomal proteins in the immunotherapy of melanoma. J. Immunother.21(4), 237–246 (1998).
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun.4, 1 (2004).
   PubMedGoogle Scholar
• Cebon J, Caballero O, John T, Klein O. Cancer Testis Antigens. In: Tumor-Associated Antigens. Gires O, Barbara S (Eds). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 161–177 (2009).
   Google Scholar
• Klein O, Ebert LM, Nicholaou T et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin. Cancer Res.15(7), 2507–2513 (2009).
   PubMed Web of Science ®Google Scholar
• Yuan J, Gnjatic S, Li H et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl Acad. Sci. USA105(51), 20410–20415 (2008).
   PubMed Web of Science ®Google Scholar
• Hoek KS, Eichhoff OM, Schlegel NC et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res.68(3), 650–656 (2008).
   PubMed Web of Science ®Google Scholar
• Kurnick JT, Ramirez-Montagut T, Boyle LA et al. A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter. J. Immunol.167(3), 1204–1211 (2001).
   PubMedGoogle Scholar
• Dunn IS, Haggerty TJ, Kono M et al. Enhancement of human melanoma antigen expression by IFN-β. J. Immunol.179(4), 2134–2142 (2007).
   PubMedGoogle Scholar
• De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell Biol.19(11), 7327–7335 (1999).
   PubMed Web of Science ®Google Scholar
• Weber J, Salgaller M, Samid D et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2’-deoxycytidine. Cancer Res.54(7), 1766–1771 (1994).
   PubMed Web of Science ®Google Scholar
• Gedye C, Quirk J, Browning J et al. Cancer/testis antigens can be immunological targets in clonogenic CD133(+) melanoma cells. Cancer Immunol. Immunother.58(10), 1635–1646 (2009).
   PubMed Web of Science ®Google Scholar
• Banchereau J, Palucka AK, Dhodapkar M et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res.61(17), 6451–6458 (2001).
   PubMed Web of Science ®Google Scholar
• Francois V, Ottaviani S, Renkvist N et al. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res.69(10), 4335–4345 (2009).
   PubMed Web of Science ®Google Scholar
• Kruit WH, Van Ojik HH, Brichard VG et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int. J. Cancer117(4), 596–604 (2005).
   PubMed Web of Science ®Google Scholar
• Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med.190(11), 1669–1678 (1999).
   PubMed Web of Science ®Google Scholar
• Adams S, O’Neill DW, Nonaka D et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol.181(1), 776–784 (2008).
   PubMed Web of Science ®Google Scholar
• Davis ID, Chen Q, Morris L et al. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J. Immunother.29(5), 499–511 (2006).
   PubMed Web of Science ®Google Scholar
• Fourcade J, Kudela P, Sun Z et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J. Immunol.182(9), 5240–5249 (2009).
   PubMed Web of Science ®Google Scholar
• Nicholaou T, Ebert L, Davis ID et al. Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol. Cell Biol.84(3), 303–317 (2006).
   PubMedGoogle Scholar
• Shackleton M, Davis ID, Hopkins W et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun.4, 9 (2004).
   PubMedGoogle Scholar
• Gnjatic S, Nishikawa H, Jungbluth AA et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv. Cancer Res.95, 1–30 (2006).
   PubMed Web of Science ®Google Scholar
• Ritter G, Livingston PO. Ganglioside antigens expressed by human cancer cells. Semin. Cancer Biol.2(6), 401–409 (1991).
   PubMedGoogle Scholar
• Chapman PB, Wu D, Ragupathi G et al. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin. Cancer Res.10(14), 4717–4723 (2004).
   PubMed Web of Science ®Google Scholar
• Chapman PB, Williams L, Salibi N, Hwu WJ, Krown SE, Livingston PO. A Phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine22(21–22), 2904–2909 (2004).
   PubMedGoogle Scholar
• Parmiani G, De Filippo A, Novellino L, Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J. Immunol.178(4), 1975–1979 (2007).
   PubMed Web of Science ®Google Scholar
• Wolfel T, Hauer M, Schneider J et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science269(5228), 1281–1284 (1995).
   PubMed Web of Science ®Google Scholar
• Karanikas V, Colau D, Baurain JF et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res.61(9), 3718–3724 (2001).
   PubMed Web of Science ®Google Scholar
• Lennerz V, Fatho M, Gentilini C et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl Acad. Sci. USA102(44), 16013–16018 (2005).
   PubMed Web of Science ®Google Scholar
• Sjoblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science314(5797), 268–274 (2006).
   PubMed Web of Science ®Google Scholar
• Yewdell JW. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity25(4), 533–543 (2006).
   PubMed Web of Science ®Google Scholar
• Segal NH, Parsons DW, Peggs KS et al. Epitope landscape in breast and colorectal cancer. Cancer Res.68(3), 889–892 (2008).
   PubMed Web of Science ®Google Scholar
• Van Stipdonk MJ, Hardenberg G, Bijker MS et al. Dynamic programming of CD8+ T lymphocyte responses. Nat. Immunol.4(4), 361–365 (2003).
   PubMed Web of Science ®Google Scholar
• Zehn D, Lee SY, Bevan MJ. Complete but curtailed T-cell response to very low-affinity antigen. Nature458(7235), 211–214 (2009).
   PubMed Web of Science ®Google Scholar
• Leignadier J, Labrecque N. Epitope density influences CD8+ memory T cell differentiation. PLoS ONE5(10), e13740 (2010).
   PubMedGoogle Scholar
• Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med.5(11), 1249–1255 (1999).
   PubMed Web of Science ®Google Scholar
• Feng H, Zeng Y, Whitesell L, Katsanis E. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood97(11), 3505–3512 (2001).
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Casares N, Pequignot MO, Chaput N, Albert ML, Kroemer G. Immune response against dying tumor cells. Adv. Immunol.84, 131–179 (2004).
   PubMedGoogle Scholar
• Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med.13(9), 1050–1059 (2007).
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Apetoh L, Tesniere A et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat. Med.15(10), 1170–1178 (2009).
   PubMed Web of Science ®Google Scholar
• Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J. Exp. Med.178(4), 1391–1396 (1993).
   PubMed Web of Science ®Google Scholar
• Blachere NE, Li Z, Chandawarkar RY et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med.186(8), 1315–1322 (1997).
   PubMed Web of Science ®Google Scholar
• Lev A, Takeda K, Zanker D et al. The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation. Immunity28(6), 787–798 (2008).
   PubMedGoogle Scholar
• Lev A, Dimberu P, Das SR et al. Efficient cross-priming of antiviral CD8+ T cells by antigen donor cells is GRP94 independent. J. Immunol.183(7), 4205–4210 (2009).
   PubMedGoogle Scholar
• Neller MA, Lopez JA, Schmidt CW. Antigens for cancer immunotherapy. Semin. Immunol.20(5), 286–295 (2008).
   PubMed Web of Science ®Google Scholar
• Hanna MG Jr, Hoover HC Jr, Pinedo HM, Finer M. Active specific immunotherapy with autologous tumor cell vaccines for stage II colon cancer: logistics, efficacy, safety and immunological pharmacodynamics. Hum. Vaccin.2(4), 185–191 (2006).
   PubMed Web of Science ®Google Scholar
• Van Den Brenk HA. Autoimmunization in human malignant melanoma. Br. Med. J.4(5676), 171–172 (1969).
   PubMedGoogle Scholar
• Currie GA, Lejeune F, Fairley GH. Immunization with irradiated tumour cells and specific lymphocyte cytotoxicity in malignant melanoma. Br. Med. J.2(5757), 305–310 (1971).
   PubMedGoogle Scholar
• Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin. Cancer Res.7(7), 1882–1887 (2001).
   PubMed Web of Science ®Google Scholar
• Dillman RO, Wiemann M, Nayak SK, Deleon C, Hood K, Depriest C. Interferon-γ or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized Phase 2 trial of the cancer biotherapy research group. J. Immunother.26(4), 367–373 (2003).
   PubMed Web of Science ®Google Scholar
• Dillman RO, Depriest C, Deleon C et al. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory Phase I/II trials in patients with metastatic melanoma. Cancer Biother. Radiopharm22(3), 309–321 (2007).
   PubMed Web of Science ®Google Scholar
• Hanna MG Jr, Peters LC. Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgery. Cancer42(6), 2613–2625 (1978).
   PubMed Web of Science ®Google Scholar
• Berd D, Maguire HC Jr, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res.46(5), 2572–2577 (1986).
   PubMed Web of Science ®Google Scholar
• Berd D, Sato T, Cohn H, Maguire HC Jr, Mastrangelo MJ. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int. J. Cancer94(4), 531–539 (2001).
   PubMed Web of Science ®Google Scholar
• Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J. Clin. Oncol.22(3), 403–415 (2004).
   PubMed Web of Science ®Google Scholar
• Morton DL, Foshag LJ, Hoon DS et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg.216(4), 463–482 (1992).
   PubMed Web of Science ®Google Scholar
• Faries MB, Morton DL. Therapeutic vaccines for melanoma: current status. BioDrugs19(4), 247–260 (2005).
   PubMedGoogle Scholar
• Eggermont AM. Immunotherapy: vaccine trials in melanoma – time for reflection. Nat. Rev. Clin. Oncol.6(5), 256–258 (2009).
   PubMedGoogle Scholar
• Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin. Cancer Res.15(22), 7029–7035 (2009).
   PubMed Web of Science ®Google Scholar
• Mitchell MS, Darrah D, Stevenson L. Therapy of melanoma with allogeneic melanoma lysates alone or with interferon-α. Cancer Invest.20(5–6), 759–768 (2002).
   PubMed Web of Science ®Google Scholar
• Sondak VK, Liu PY, Tuthill RJ et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J. Clin. Oncol.20(8), 2058–2066 (2002).
   PubMed Web of Science ®Google Scholar
• Mitchell MS, Harel W, Groshen S. Association of HLA phenotype with response to active specific immunotherapy of melanoma. J. Clin. Oncol.10(7), 1158–1164 (1992).
   PubMed Web of Science ®Google Scholar
• Sosman JA, Unger JM, Liu PY et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J. Clin. Oncol.20(8), 2067–2075 (2002).
   PubMed Web of Science ®Google Scholar
• Wallack MK, Steplewski Z, Koprowski H et al. A new approach in specific, active immunotherapy. Cancer39(2), 560–564 (1977).
   PubMed Web of Science ®Google Scholar
• Wallack MK, Sivanandham M. Clinical trials with VMO for melanoma. Ann. N Y Acad. Sci.690, 178–189 (1993).
   PubMedGoogle Scholar
• Wallack MK, Sivanandham M, Balch CM et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a Phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J. Am. Coll. Surg.187(1), 69–77; discussion 77–69 (1998).
   PubMed Web of Science ®Google Scholar
• Hersey P, Coates AS, Mccarthy WH et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J. Clin. Oncol.20(20), 4181–4190 (2002).
   PubMed Web of Science ®Google Scholar
• Palmer K, Moore J, Everard M et al. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum. Gene Ther.10(8), 1261–1268 (1999).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Kampgen E, Wagner E et al. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a Phase I study. Hum. Gene Ther.10(6), 983–993 (1999).
   PubMed Web of Science ®Google Scholar
• Hege KM, Jooss K, Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int. Rev. Immunol.25(5–6), 321–352 (2006).
   PubMed Web of Science ®Google Scholar
• Pinzon-Charry A, Ho CS, Laherty R et al. A population of HLA-DR+ immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer. Neoplasia7(12), 1112–1122 (2005).
   PubMed Web of Science ®Google Scholar
• Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med.4(3), 328–332 (1998).
   PubMed Web of Science ®Google Scholar
• O’Rourke MG, Johnson M, Lanagan C et al. Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother.52(6), 387–395 (2003).
   PubMed Web of Science ®Google Scholar
• Dillman RO, Selvan SR, Schiltz PM. Patient-specific dendritic-cell vaccines for metastatic melanoma. N. Engl. J. Med.355(11), 1179–1181 (2006).
   PubMed Web of Science ®Google Scholar
• Dillman RO, Nanci AA, Williams ST et al. Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine. Cancer Biother. Radiopharm25(5), 553–557 (2010).
   PubMed Web of Science ®Google Scholar
• Lopez MN, Pereda C, Segal G et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor β-expressing T cells. J. Clin. Oncol.27(6), 945–952 (2009).
   PubMed Web of Science ®Google Scholar
• Markovic SN, Dietz AB, Greiner CW et al. Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma. J. Transl Med.4, 35 (2006).
   PubMed Web of Science ®Google Scholar
• Kyte JA, Mu L, Aamdal S et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther.13(10), 905–918 (2006).
   PubMed Web of Science ®Google Scholar
• Van Nuffel AM, Corthals J, Neyns B, Heirman C, Thielemans K, Bonehill A. Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation. Methods Mol. Biol.629, 405–452 (2010).
   PubMedGoogle Scholar
• Heiser A, Coleman D, Dannull J et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest.109(3), 409–417 (2002).
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Heiser A et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res.63(9), 2127–2133 (2003).
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Yamanaka R, Homma J et al. Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma. Cancer Immunol. Immunother.52(10), 632–637 (2003).
   PubMed Web of Science ®Google Scholar
• Schuurhuis DH, Verdijk P, Schreibelt G et al. In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res.69(7), 2927–2934 (2009).
   PubMed Web of Science ®Google Scholar
• Smith AL, Fazekas De St Groth B. Antigen-pulsed CD8α+ dendritic cells generate an immune response after subcutaneous injection without homing to the draining lymph node. J. Exp. Med.189(3), 593–598 (1999).
   PubMed Web of Science ®Google Scholar
• Dolan BP, Gibbs KD Jr, Ostrand-Rosenberg S. Tumor-specific CD4+ T cells are activated by “cross-dressed” dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. J. Immunol.176(3), 1447–1455 (2006).
   PubMed Web of Science ®Google Scholar
• Belli F, Testori A, Rivoltini L et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol.20(20), 4169–4180 (2002).
   PubMed Web of Science ®Google Scholar
• Di Pietro A, Tosti G, Ferrucci PF, Testori A. Heat shock protein peptide complex 96-based vaccines in melanoma: how far we are, how far we can get. Hum. Vaccin.5(11), 727–737 (2009).
   Web of Science ®Google Scholar
• Testori A, Richards J, Whitman E et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C-100–121 Study Group. J. Clin. Oncol.26(6), 955–962 (2008).
   PubMed Web of Science ®Google Scholar
• Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv. Exp. Med. Biol.667, 111–123 (2009).
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity33(4), 492–503 (2010).
   PubMed Web of Science ®Google Scholar
• Urosevic M, Dummer R. Role of imiquimod in skin cancer treatment. Am. J. Clin. Dermatol.5(6), 453–458 (2004).
   PubMed Web of Science ®Google Scholar
• Pashenkov M, Goess G, Wagner C et al. Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol.24(36), 5716–5724 (2006).
   PubMed Web of Science ®Google Scholar
• Speiser DE, Lienard D, Rufer N et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest.115(3), 739–746 (2005).
   PubMed Web of Science ®Google Scholar
• Kruit WH, Suciu S, Dreno B et al. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label Phase II study of the EORTC Melanoma Group. J. Clin. Oncolol26(Suppl.), (2008) (Abstract 9065s).
   Google Scholar
• Maraskovsky E, Schnurr M, Wilson NS, Robson NC, Boyle J, Drane D. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunol. Cell Biol.87(5), 371–376 (2009).
   PubMedGoogle Scholar
• Schnurr M, Orban M, Robson NC et al. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. J. Immunol.182(3), 1253–1259 (2009).
   PubMed Web of Science ®Google Scholar
• Robson NC, Mcalpine T, Knights AJ et al. Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery. Blood116(2), 218–225 (2010).
   PubMedGoogle Scholar
• Maraskovsky E, Sjolander S, Drane DP et al. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin. Cancer Res.10(8), 2879–2890 (2004).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol.17(7), 2105–2116 (1999).
   PubMed Web of Science ®Google Scholar
• Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon α adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J. Natl Cancer Inst.102(7), 493–501 (2010).
   PubMed Web of Science ®Google Scholar
• Gogas H, Ioannovich J, Dafni U et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med.354(7), 709–718 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med.4(3), 321–327 (1998).
   PubMed Web of Science ®Google Scholar
• Sosman JA, Carrillo C, Urba WJ et al. Three Phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J. Clin. Oncol.26(14), 2292–2298 (2008).
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson D, Richards J et al. A Phase III multi-institutional randomized study of immunization with the gp100:209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J. Clin. Oncol.27(Suppl.), 18s (2009) (Abstract CRA9011).
   Google Scholar
• Mitchell MS, Abrams J, Thompson JA et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon α-2b compared with high-dose interferon α-2b for resected stage III cutaneous melanoma. J. Clin. Oncol.25(15), 2078–2085 (2007).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Lee S, Moschos SJ et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-α2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin. Cancer Res.15(4), 1443–1451 (2009).
   PubMed Web of Science ®Google Scholar
• Spitler LE, Grossbard ML, Ernstoff MS et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol.18(8), 1614–1621 (2000).
   PubMed Web of Science ®Google Scholar
• Daud AI, Mirza N, Lenox B et al. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J. Clin. Oncol.26(19), 3235–3241 (2008).
   PubMed Web of Science ®Google Scholar
• Weber J, Sondak VK, Scotland R et al. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer97(1), 186–200 (2003).
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Petroni GR, Olson WC et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin. Cancer Res.15(22), 7036–7044 (2009).
   PubMed Web of Science ®Google Scholar
• Davis ID, Brady B, Kefford RF et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a Phase IIa trial. Clin. Cancer Res.15(6), 2123–2129 (2009).
   PubMed Web of Science ®Google Scholar
• Pellegrini M, Calzascia T, Elford AR et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat. Med.15(5), 528–536 (2009).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Sportes C, Ahmadzadeh M et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J. Immunother.29(3), 313–319 (2006).
   PubMed Web of Science ®Google Scholar
• Sportes C, Hakim FT, Memon SA et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med.205(7), 1701–1714 (2008).
   PubMed Web of Science ®Google Scholar
• Olivares J, Kumar P, Yu Y et al. Phase I trial of TGF-{β}2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin. Cancer Res.17(1), 183–192 (2011).
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized Phase III trial of the DC study group of the DeCOG. Ann. Oncol.17(4), 563–570 (2006).
   PubMed Web of Science ®Google Scholar
• O’Neill DW, Adams S, Goldberg JD et al. Comparison of the immunogenicity of Montanide ISA 51 adjuvant and cytokine-matured dendritic cells in a randomized controlled clinical trial of melanoma vaccines J. Clin. Oncol.27, 15S (2009) (Abstract 3002).
   Google Scholar
• Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat. Rev.7(7), 543–555 (2007).
   Google Scholar
• Villadangos JA, Shortman K. Found in translation: the human equivalent of mouse CD8+ dendritic cells. J. Exp. Med.207(6), 1131–1134 (2010).
   PubMed Web of Science ®Google Scholar
• Tacken PJ, De Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev.7(10), 790–802 (2007).
   Google Scholar
• Mahnke K, Qian Y, Fondel S, Brueck J, Becker C, Enk AH. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res.65(15), 7007–7012 (2005).
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science (New York, NY)271(5256), 1734–1736 (1996).
   Google Scholar
• Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA99(19), 12293–12297 (2002).
   PubMed Web of Science ®Google Scholar
• Melero I, Martinez-Forero I, Dubrot J, Suarez N, Palazon A, Chen L. Palettes of vaccines and immunostimulatory monoclonal antibodies for combination. Clin. Cancer Res.15(5), 1507–1509 (2009).
   PubMed Web of Science ®Google Scholar
• Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol.23(25), 6043–6053 (2005).
   PubMed Web of Science ®Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA100(8), 4712–4717 (2003).
   PubMed Web of Science ®Google Scholar
• Ribas A, Comin-Anduix B, Chmielowski B et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin. Cancer Res.15(19), 6267–6276 (2009).
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Johnson LA, Heemskerk B et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood114(8), 1537–1544 (2009).
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol.28(19), 3167–3175 (2010).
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA107(9), 4275–4280
   PubMedGoogle Scholar
• Gray JC, French RR, James S, Al-Shamkhani A, Johnson PW, Glennie MJ. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. Eur. J. Immunol.38(9), 2499–2511 (2008).
   PubMed Web of Science ®Google Scholar
• Jandus C, Bioley G, Speiser DE, Romero P. Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. Cancer Immunol. Immunother.57(12), 1795–1805 (2008).
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Felipe-Silva A, Heemskerk B et al. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood112(13), 4953–4960 (2008).
   PubMed Web of Science ®Google Scholar
• Filipazzi P, Valenti R, Huber V et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol.25(18), 2546–2553 (2007).
   PubMed Web of Science ®Google Scholar
• Mandruzzato S, Solito S, Falisi E et al. IL4Rα+ myeloid-derived suppressor cell expansion in cancer patients. J. Immunol.182(10), 6562–6568 (2009).
   PubMed Web of Science ®Google Scholar
• Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-SIGN. Cancer Res.70(11), 4335–4345 (2010).
   PubMed Web of Science ®Google Scholar
• Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood107(2), 628–636 (2006).
   PubMed Web of Science ®Google Scholar
• Klages K, Mayer CT, Lahl K et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res.70(20), 7788–7799 (2010).
   PubMed Web of Science ®Google Scholar
• Mahnke K, Schonfeld K, Fondel S et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer120(12), 2723–2733 (2007).
   PubMed Web of Science ®Google Scholar
• Jacobs JF, Punt CJ, Lesterhuis WJ et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a Phase I/II study in metastatic melanoma patients. Clin. Cancer Res.16(20), 5067–5078 (2010).
   PubMed Web of Science ®Google Scholar
• Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res.70(12), 4850–4858 (2010).
   PubMed Web of Science ®Google Scholar
• Kusmartsev S, Su Z, Heiser A et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin. Cancer Res.14(24), 8270–8278 (2008).
   PubMed Web of Science ®Google Scholar
• Marchand M, Punt CJ, Aamdal S et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur. J. Cancer39(1), 70–77 (2003).
   PubMed Web of Science ®Google Scholar
• Soiffer R, Hodi FS, Haluska F et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol.21(17), 3343–3350 (2003).
   PubMed Web of Science ®Google Scholar
• Luiten RM, Kueter EW, Mooi W et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J. Clin. Oncol.23(35), 8978–8991 (2005).
   PubMed Web of Science ®Google Scholar
• O’rourke MG, Johnson MK, Lanagan CM et al. Dendritic cell immunotherapy for stage IV melanoma. Melanoma Res.17(5), 316–322 (2007).
   PubMed Web of Science ®Google Scholar
• Dillman RO, Selvan SR, Schiltz PM et al. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. Cancer Biother. Radiopharm24(3), 311–319 (2009).
   PubMed Web of Science ®Google Scholar
• Morton DL, Mozzillo N, Thompson JF et al. An international, randomized, Phase III trial of bacillus Calmette–Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J. Clin. Oncol.25(18S), 474s (2007).
   Web of Science ®Google Scholar
• Bakker AB, Schreurs MW, De Boer AJ et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med.179(3), 1005–1009 (1994).
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Sakaguchi K et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med.180(1), 347–352 (1994).
   PubMed Web of Science ®Google Scholar
• Hofmann O, Caballero OL, Stevenson BJ et al. Genome-wide analysis of cancer/testis gene expression. Proc. Natl Acad. Sci. USA105(51), 20422–20427 (2008).
   PubMed Web of Science ®Google Scholar